Pfizer (NYSE:PFE) is set to report its Q3 2018 earnings on October 30, and we expect the company to post steady top line growth, primarily led by a ramp up in Ibrance sales, along with Eliquis, which has seen market share gains in the recent quarters. Also, the company will likely benefit from...
Pfizer (NYSE:PFE) is set to report its Q3 2018 earnings on October 30, and we expect the company to post steady top line growth, primarily led by a ramp up in Ibrance sales, along with Eliquis, which has seen market share gains in the recent quarters. Also, the company will likely benefit from...
Share this Article
Recommended